Confirmation of Location Decision
Hemostemix PR, a wholly owned subsidiary of the biotech company Hemostemix (TSXV:HEM; FRA:2VF0), will use the Luis Muñoz Marín International Airport (SJU) in Puerto Rico as a state-of-the-art logistics center for its autologous blood-based stem cell therapy in the future. The airport has just received the prestigious CEIV Pharma certification from the International Air Transport Association (IATA), putting it on par with international hubs like Miami or Amsterdam. This certification strengthens Puerto Rico’s status as a global hub for logistics services for biologics and pharmaceutical products.
The CEIV Pharma certification ensures the highest standards in handling, storage, and transport of biologics and pharmaceutical products, meeting strict international quality and safety criteria. With this certification, SJU joins an elite group of major global hubs and further establishes Puerto Rico as a strategic node in the global supply chain for biologics and pharmaceuticals.
Thomas Smeenk, President and CEO of Hemostemix PR Inc., commented: “The achievement of CEIV Pharma certification by Luis Muñoz Marín International Airport is a testament to Puerto Rico’s commitment to excellence in biologics and pharmaceutical logistics. This certification provides Hemostemix PR Inc. with access to a world-leading, certified logistics center for biologics and enables efficient delivery of ACP-01 therapies to patients worldwide.”
Hemostemix sees the upgrade of the airport in Puerto Rico as confirmation of its location decision for the country. The smooth logistics support Hemostemix PR’s mission to improve patient treatment outcomes worldwide through innovative regenerative therapies. SJU’s robust, certified infrastructure ensures that sensitive biological preparations like ACP-01 are transported with the utmost care and compliance, meeting Hemostemix’s stringent requirements.
